aibio
Company Updates ·
Quoin publishes peer-reviewed paper on QRX003 in Netherton Syndrome
The paper, published online on October 13, 2026, includes a pediatric compassionate-use case report. Quoin also described interim results from its Phase 2/3 study.
QNRX Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals (QNRX) news QNRX going concern and offering news
Latest Quoin Pharmaceuticals news
- Company Updates
EMA grants orphan drug designation for QRX003 in peeling skin syndrome
The designation is the eighth regulatory milestone for QRX003, according to the company. If QRX003 is approved in the EU, it would receive 10 years of market exclusivity.
- Company Updates
FDA grants fast track designation for QRX003 in peeling skin syndrome
The designation is the second Fast Track for QRX003, after Netherton Syndrome in March 2026. It follows an IND that the FDA cleared in July 2026.
- Company Updates
FDA grants rare pediatric disease designation for QRX003 in peeling skin syndrome
The designation is the second Rare Pediatric Disease Designation for QRX003. Quoin said an approved application could qualify it for a priority review voucher.
- Financings
Quoin Pharmaceuticals agrees to private placement with about $30.8 million upfront
Quoin agreed to sell 6,305,300 ADSs or pre-funded warrants at $4.88 and warrants for up to 3,152,650 ADSs, for about $30.8 million at closing. The same day it reported interim results from six patients, and its 10-K carries a going-concern warning.
- Company Updates
Quoin reports second quarter 2026 results and QRX003 progress
Quoin said it had about $10.8 million in cash, cash equivalents and marketable securities as of June 30, 2026, and that it expects that position to fund operations into 2027.
- Company Updates
FDA conditionally accepts QYLEKI as the brand name for QRX003
The FDA conditionally accepted QYLEKI as the proposed brand name for QRX003 in Netherton Syndrome, and the company says a pivotal Phase 3 study is expected to start in the second half of 2026.
- Company Updates
Quoin reports first quarter 2026 results and FDA meeting outcome
Quoin said an FDA Type C meeting indicated a single Phase 3 study may be sufficient for U.S. approval of QRX003, and reported approximately $14 million in cash as of March 31, 2026.
- Financings
Quoin closes $16.6 million private placement, warrants could add up to $88.0 million
Quoin sold ADSs and pre-funded warrants with four series of warrants whose cash exercise depends on FDA and trial events that the filings do not report as having happened. Maxim Group LLC was the exclusive placement agent, and director Dennis Langer took part.
- Listings
Quoin Pharmaceuticals regains compliance with Nasdaq $1.00 minimum bid price rule
Nasdaq said on April 29, 2025 that Quoin's ADSs closed at $1.00 or more from April 9 to April 28, closing the minimum bid price matter. The company says it has no commercialized product and has generated no revenue to date.
- Financings
Quoin Pharmaceuticals prices $6.8 million offering of ADSs and warrants at $0.45
Quoin Pharmaceuticals priced a $6.8 million offering at $0.45 per ADS, below the $0.647 close on December 19. Older warrants were repriced to the same level, and the prospectus sets no minimum amount for the deal to close.
What Quoin Pharmaceuticals does
Quoin Pharmaceuticals, Ltd. is a late-stage clinical specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases. Its lead product, QRX003, is a topical lotion being developed for Netherton Syndrome, a rare hereditary genetic disease. The company says QRX003 is entering pivotal registrational clinical testing under an open Investigational New Drug application with the FDA. QRX003 is also being developed for Peeling Skin Syndrome, and the company plans to pursue Ichthyosis related disorders and SAM Syndrome. The company has opened six clinical sites in the United States and has entered into 9 commercial partnerships for QRX003 spanning 61 countries outside its core territories. A research agreement with the Queensland University of Technology covers QRX008, a potential treatment for scleroderma at early-stage development. A research agreement with University College Cork covers topical rapamycin formulations for rare and orphan diseases. The text says no products have been commercialized and no revenue has been generated to date.
| Product or program | What it is | Stage |
|---|---|---|
| QRX003 | Topical lotion for Netherton Syndrome and Peeling Skin Syndrome | entering pivotal registrational clinical testing |
| QRX008 | Small molecule VLA-4 inhibitor for scleroderma, licensed from QUT research | early-stage development |
| Topical rapamycin (QRX009) | Rapamycin formulations for rare and orphan diseases under a UCC research agreement | research |
Quoin Pharmaceuticals annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $9.8 million | $3.6 million |
| Net income (loss) | -$15.8 million | -$9.0 million |
| Cash from operations | -$13.5 million | -$7.9 million |
| Cash and equivalents | $3.8 million | $3.6 million |
| Short-term investments | $14.9 million | $10.4 million |
Questions about Quoin Pharmaceuticals
Has Quoin Pharmaceuticals issued a going-concern warning?
Our latest story on this, dated Aug 28, 2026: "Quoin Pharmaceuticals agrees to private placement with about $30.8 million upfront". The story links the filing or release it is based on. Read the story.
Has Quoin Pharmaceuticals raised money recently?
Our latest story on this, dated Aug 28, 2026: "Quoin Pharmaceuticals agrees to private placement with about $30.8 million upfront". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Quoin Pharmaceuticals?
Quoin Pharmaceuticals, Ltd. trades under the ticker QNRX on NASDAQ.
Where is Quoin Pharmaceuticals listed?
Quoin Pharmaceuticals, Ltd. is listed on NASDAQ.
What is the SEC CIK of Quoin Pharmaceuticals?
The SEC Central Index Key (CIK) for Quoin Pharmaceuticals, Ltd. is 1671502. Its filings are on SEC EDGAR.
How many shares does Quoin Pharmaceuticals have outstanding?
70,294,615 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-14.
Which country or territory is Quoin Pharmaceuticals listed under?
Our directory records Quoin Pharmaceuticals, Ltd. under United States.
What does Quoin Pharmaceuticals do?
Our directory classifies Quoin Pharmaceuticals, Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Quoin Pharmaceuticals?
The ISIN recorded for Quoin Pharmaceuticals, Ltd. is US74907L4095.
Does aibio.space cover Quoin Pharmaceuticals?
aibio.space lists Quoin Pharmaceuticals, Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Quoin Pharmaceuticals incorporated?
SEC records list its state or country of incorporation as L3.
What does Quoin Pharmaceuticals develop?
Quoin Pharmaceuticals, Ltd. is a late-stage clinical specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases. Its lead product, QRX003, is a topical lotion being developed for Netherton Syndrome, a rare hereditary genetic disease.
What is QRX003 from Quoin Pharmaceuticals?
QRX003: Topical lotion for Netherton Syndrome and Peeling Skin Syndrome Stage: entering pivotal registrational clinical testing.
What is QRX008 from Quoin Pharmaceuticals?
QRX008: Small molecule VLA-4 inhibitor for scleroderma, licensed from QUT research Stage: early-stage development.
Is Quoin Pharmaceuticals profitable?
Quoin Pharmaceuticals, Ltd. reported a net loss of $15.8 million for the fiscal year ended Dec 31, 2025, and used $13.5 million of cash in operations, per its annual report to the SEC.
Investor discussion: Quoin Pharmaceuticals
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 3.03). Source
- Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
- Financings
Reported a financing. SEC Form 424B4. Source
- Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Stock chart
SEC filings and registration
- SEC name
- Quoin Pharmaceuticals Ltd.
- CIK
- 1671502
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- QNRX (Nasdaq)
- State or country of incorporation
- L3
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 42127 PLEASANT FOREST COURT, ASHBURN, VA, 20148-7349
- Phone
- 703 980 4182
- Shares outstanding
- 70,294,615 as of 2026-08-12 (10-Q filed 2026-08-14)
- Former names
- Quoin Pharmaceuticals, Ltd.; Cellect Biotechnology Ltd.; Cellect Biomed Ltd.
Recent filings
Listing details
- Company
- Quoin Pharmaceuticals, Ltd.
- Ticker
- QNRX
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US74907L4095
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction